Adial Pharmaceuticals Stock (NASDAQ:ADIL)
Previous Close
$0.69
52W Range
$0.61 - $3.10
50D Avg
$0.77
200D Avg
$0.98
Market Cap
$4.44M
Avg Vol (3M)
$817.21K
Beta
1.26
Div Yield
-
ADIL Company Profile
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
ADIL Performance
Peer Comparison
| Ticker | Company |
|---|---|
| AXLA | Axcella Health Inc. |
| ALRN | Aileron Therapeutics, Inc. |
| ONTX | Traws Pharma, Inc. |
| DFFN | CervoMed Inc. |
| ATXI | Avenue Therapeutics, Inc. |
| TNXP | Tonix Pharmaceuticals Holding Corp. |
| CBIO | Gyre Therapeutics, Inc. |
| BNTC | Benitec Biopharma Inc. |
| AEZS | COSCIENS Biopharma Inc. |
| BPTH | Bio-Path Holdings, Inc. |
| HOTH | Hoth Therapeutics, Inc. |
| NRBO | NeuroBo Pharmaceuticals, Inc. |